#ASCO24: A roundup of the latest data from Merus, MorphoSys and others

Read on for news about Im­muno­core, Ar­cus, CG On­col­o­gy, Gen­mab, Mer­ck and GSK:

Merus stock spikes on da­ta in head and neck squa­mous cell car­ci­no­ma: The biotech’s shares $MRUS rose more than 20% on Fri­day morn­ing af­ter shar­ing a Phase 2 tri­al as­sess­ing petosem­tam­ab with Mer­ck’s Keytru­da as a first-line treat­ment. Among 10 pa­tients evalu­able for ef­fi­ca­cy, there was one com­plete re­sponse and five par­tial re­spons­es (two con­firmed and three un­con­firmed as of the da­ta cut­off). Merus is ex­pect­ed to re­lease more da­ta about the com­bo on Tues­day. — Max Gel­man

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.